Figure 12. The role of ICI scores in the prediction of immunotherapeutic benefits. (A) RUNX2 expression in groups with a different anti-PD-1 clinical response status in the GSE78220. (B) RUNX2 expression in groups with a different anti-PD-L1 clinical response status in the IMvigor210 cohort. (C) RUNX1 expression in groups with a different anti-PD-L1 clinical response status in the IMvigor210 cohort.